This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Johnson & Johnson
Drug Names(s): CNTO 1959, CNTO1959
Description: Guselkumab is a fully human monoclonal antibody targeting the p19 subunit of IL-23. By contrast, Stelara binds to the p40 subunit of IL-23 as well as IL12. Thus, guselkumab may offer more specificity of inhibition for IL-23.
Deal Structure: In December 2004, Morphosys AG announced the extension of an agreement with Centocor Inc., a Johnson & Johnson company,until the end of 2007. The objective of the cooperation between MorphoSys and Centocor is thedevelopment of fully human therapeutic antibodies in a broad range of indications. Thecooperation agreement, originally signed in December 2000, was to end in December 2005.
Within the framework of the extended agreement, the two parties undertake to commence atleast two new antibody development programs in 2005. Furthermore, the agreement alsoprovides for increased levels of research and development funding by Centocor to MorphoSys,and an upfront payment by Centocor to MorphoSys for the extension. Further financial detailswere not disclosed.
Under the extended agreement, Centocor has the option to elect up to 30 disease-related targetmolecules, against which the two parties will develop fully human, optimized antibodies usingthe HuCAL GOLD technology of MorphoSys....See full deal structure in Biomedtracker
Partners: MorphoSys AG
Additional information available to subscribers only: